• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pharmacokinetics of Losartan and its Active Metabolite EXP3174 in Healthy Iranian Subjects.

作者信息

Amini Hossein, Ahmadiani Abolhassan, Moazenzadeh Maryam

机构信息

Laboratory of Bioanalysis, Neuroscience Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

Clin Drug Investig. 2004;24(10):619-23. doi: 10.2165/00044011-200424100-00008.

DOI:10.2165/00044011-200424100-00008
PMID:17523724
Abstract
摘要

相似文献

1
Pharmacokinetics of Losartan and its Active Metabolite EXP3174 in Healthy Iranian Subjects.氯沙坦及其活性代谢物EXP3174在伊朗健康受试者中的药代动力学
Clin Drug Investig. 2004;24(10):619-23. doi: 10.2165/00044011-200424100-00008.
2
Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans.氯沙坦（一种血管紧张素II受体拮抗剂）及其活性代谢物EXP3174在人体内的药代动力学。
Clin Pharmacol Ther. 1995 Dec;58(6):641-9. doi: 10.1016/0009-9236(95)90020-9.
3
Evaluation of [(11)C]methyl-losartan and [(11)C]methyl-EXP3174 for PET imaging of renal AT1receptor in rats.[(11)C]甲基氯沙坦和[(11)C]甲基EXP3174用于大鼠肾脏AT1受体PET成像的评估。
Nucl Med Biol. 2015 Nov;42(11):850-7. doi: 10.1016/j.nucmedbio.2015.06.012. Epub 2015 Jun 30.
4
Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects.单个CYP2C9*3等位基因对健康日本受试者中氯沙坦药代动力学和药效学的影响。
Eur J Clin Pharmacol. 2003 Nov;59(8-9):589-92. doi: 10.1007/s00228-003-0664-5. Epub 2003 Sep 19.
5
The effect of tripterygium glucoside tablet on pharmacokinetics of losartan and its metabolite EXP3174 in rats.雷公藤多苷片对大鼠氯沙坦及其代谢产物EXP3174药代动力学的影响。
Biomed Chromatogr. 2017 Oct;31(10). doi: 10.1002/bmc.3973. Epub 2017 Apr 24.
6
Influence of compound danshen tablet on the pharmacokinetics of losartan and its metabolite EXP3174 by liquid chromatography coupled with mass spectrometry.复方丹参片对氯沙坦及其代谢产物EXP3174药代动力学的影响：液相色谱-质谱联用研究
Biomed Chromatogr. 2013 Sep;27(9):1219-24. doi: 10.1002/bmc.2930. Epub 2013 May 30.
7
Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus.对链脲佐菌素诱导的糖尿病大鼠静脉注射和口服氯沙坦后，氯沙坦及其代谢产物EXP3174的药代动力学。
Res Commun Mol Pathol Pharmacol. 1998 Aug;101(2):147-58.
8
Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.血管紧张素II受体拮抗剂氯沙坦（DuP 753）在人肝微粒体中的氧化作用。细胞色素P4503A(4)在活性代谢物EXP3174形成中的作用。
Drug Metab Dispos. 1995 Feb;23(2):285-9.
9
The physicochemical properties, in vitro metabolism and pharmacokinetics of a novel ester prodrug of EXP3174.新型 EXP3174 酯前药的理化性质、体外代谢和药代动力学。
Mol Pharm. 2010 Dec 6;7(6):2132-40. doi: 10.1021/mp100166c. Epub 2010 Oct 1.
10
Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan.非肽类血管紧张素II受体拮抗剂：氯沙坦的活性代谢物EXP3174在大鼠体内的药代动力学和药效学
Pharmacology. 1996 Jan;52(1):25-9. doi: 10.1159/000139357.

引用本文的文献

1
Allisartan ameliorates vascular remodeling through regulation of voltage-gated potassium channels in hypertensive rats.奥美沙坦通过调节高血压大鼠电压门控钾通道改善血管重构。
BMC Pharmacol Toxicol. 2021 Jun 9;22(1):33. doi: 10.1186/s40360-021-00498-7.
2
Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension.阿利沙坦酯片对轻中度原发性高血压患者血压及靶器官损伤的影响
Medicine (Baltimore). 2019 Mar;98(12):e14907. doi: 10.1097/MD.0000000000014907.

本文引用的文献

1
Allele frequency of CYP2C9 gene polymorphisms in Iran.
Thromb Haemost. 2002 Nov;88(5):874-5.
2
Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.氯沙坦及其代谢物E-3174与CYP2C9基因分型相关的药代动力学
Clin Pharmacol Ther. 2002 Jan;71(1):89-98. doi: 10.1067/mcp.2002.121216.
3
Role of CYP2C9 polymorphism in losartan oxidation.CYP2C9基因多态性在氯沙坦氧化中的作用。
Drug Metab Dispos. 2001 Jul;29(7):1051-6.
4
Determination of plasma concentrations of losartan in patients by HPLC using solid phase extraction and UV detection.采用固相萃取和紫外检测的高效液相色谱法测定患者血浆中氯沙坦的浓度。
Int J Pharm. 2000 Aug 25;204(1-2):17-22. doi: 10.1016/s0378-5173(00)00453-1.
5
The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers.CYP2C9抑制剂氟伐他汀对健康志愿者中氯沙坦药代动力学的影响。
J Clin Pharmacol. 1999 Apr;39(4):418-24. doi: 10.1177/00912709922007886.
6
Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174.
Clin Pharmacol Ther. 1999 Mar;65(3):348-52. doi: 10.1016/S0009-9236(99)70114-1.
7
Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174.氟康唑而非伊曲康唑可降低氯沙坦向E-3174的代谢。
Eur J Clin Pharmacol. 1998 Feb;53(6):445-9. doi: 10.1007/s002280050405.
8
Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension.
Pharmacol Ther. 1997;74(2):181-94. doi: 10.1016/s0163-7258(97)82002-5.
9
Clinical pharmacology of multiple-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension.
J Clin Pharmacol. 1996 May;36(5):403-8. doi: 10.1002/j.1552-4604.1996.tb05026.x.
10
Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans.氯沙坦（一种血管紧张素II受体拮抗剂）及其活性代谢物EXP3174在人体内的药代动力学。
Clin Pharmacol Ther. 1995 Dec;58(6):641-9. doi: 10.1016/0009-9236(95)90020-9.